Skip Navigation

Japanese Journal of Clinical Oncology 2008 38(9):596-603; doi:10.1093/jjco/hyn076
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ishida, K.
Right arrow Articles by Onji, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishida, K.
Right arrow Articles by Onji, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Treatment of Hepatocellular Carcinoma Using Arterial Chemoembolization with Degradable Starch Microspheres and Continuous Arterial Infusion of 5-Fluorouracil

Kiyotaka Ishida, Masashi Hirooka, Atsushi Hiraoka, Teru Kumagi, Takahide Uehara, Yoichi Hiasa, Norio Horiike and Morikazu Onji

Third Department of Internal Medicine, Ehime University School of Medicine, Touon, Ehime, Japan

For reprints and all correspondence: Morikazu Onji, Third Department of Internal Medicine, Ehime University School of Medicine, Shizukawa, Touon, Ehime 791-0295, Japan. E-mail: onjimori{at}m.ehime-u.ac.jp

Received April 4, 2008; accepted July 17, 2008

Objective: Transcatheter arterial embolization (TAE) with gelatin sponge particles and iodized oil often yields poor results when used to treat unresectable multifocal hepatocellular carcinoma (HCC). The present study retrospectively investigated the utility of a novel combination chemotherapy regimen for treating multifocal HCC resistant to TAE.

Methods: Thirteen consecutive patients with unresectable multifocal HCC and resistance to TAE were treated with combination chemotherapy consisting of arterial chemoembolization with degradable starch microspheres (DSM) (150–4500 mg on Day 1), mitomycin-C (4–8 mg on Day 1), continuous arterial infusion of 5-fluorouracil (1250 mg/120 h), cisplatin (25–50 mg/120 h) and l-leucovorin (125 mg/120 h) for 10–19 weeks.

Results: The response rate was 84.6%, with complete response in one patient and partial response (PR) in 10 patients. In four of 10 patients with PR, the tumor was not observable, although the tumor marker did not completely decline to the normal range. The 1-, 2- and 3-year survival rates were 100, 28.9 and 9.6% in all, and 100, 33.3 and 0% in six patients with portal vein tumor thrombosis (PVTT). The median survival was 22.1 months in all and 17.1 months in six patients with PVTT. Thrombocytopenia of Grade III or higher was observed in eight patients. Laparoscopic splenectomy was performed before therapy in four patients with platelet counts of <70 000/mm3, and during therapy in five patients with severe thrombocytopenia.

Conclusions: This novel chemotherapy regimen achieved favorable results and may be useful in treating patients with unresectable multifocal HCC resistant to TAE.

Key Words: hepatocellular carcinoma • degradable starch microspheres • transcatheter arterial embolization • hepatic arterial infusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.